Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1

Lucas Rischka; Matej Murgaš; Verena Pichler; Chrysoula Vraka; Ivo Rausch; Dietmar Winkler; Lukas Nics; Sazan Rasul; Leo Robert Silberbauer; Murray Bruce Reed; Godber Mathis Godbersen; Jakob Unterholzner; Patricia Handschuh; Gregor Gryglewski; Thomas Mindt; Markus Mitterhauser; Andreas Hahn; Simon Mensah Ametamey; Wolfgang Wadsak; Rupert Lanzenberger; Marcus Hacker

doi:10.1186/s13550-022-00925-8

Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[¹¹C]Me-NB1

Lucas Rischka
, Matej Murgaš
, Verena Pichler
, Chrysoula Vraka
, Ivo Rausch
, Dietmar Winkler
, Lukas Nics
, Sazan Rasul
, Leo Robert Silberbauer
, Murray Bruce Reed
, Godber Mathis Godbersen
, Jakob Unterholzner
, Patricia Handschuh
, Gregor Gryglewski
, Thomas Mindt
, Markus Mitterhauser
, Andreas Hahn
, Simon Mensah Ametamey
, Wolfgang Wadsak
, Rupert Lanzenberger

Marcus Hacker

Publications: Contribution to journal › Article › Peer Reviewed

Original language	English
Article number	53
Number of pages	8
Journal	EJNMMI Research
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s13550-022-00925-8
Publication status	Published - 2022

Funding

This project was supported in part by the Swiss National Science Foundation grant numbers 310030E-160403/1 and 310030E-182872/1 to Prof. Simon M. Ametamey. Matej Murgaš is funded by the Austrian Science Fund FWF DOC 33-B27. Murray B. Reed and Leo R. Silberbauer are recipients of a DOC fellowship of the Austrian Academy of Sciences. The authors are particularly grateful to Pia Baldinger-Melich and Paul Michenthaler for clinical support. We thank Vera Ritter, Christoph Wotawa, Daniel Pacher, Sebastian Klug, Harald Ibeschitz, Natalie Schindler, Karsten Bamminger, Tim Wollenweber and Marius Ozenil for technical support. Furthermore, the authors also thank Yves Auberson and Nicholas Seneca from Novartis for their technical support. S. M. Ametamey is co-inventor of the filed patent number US2017/0224852A1. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue. Without relevance to this work, W. Wadsak received within the last 3 years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (Fürstenfeldbruck, Germany). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Austrian Fields of Science 2012

104020 Radiochemistry

Keywords

Biodistribution
Dosimetry
GluN2B-subunit
Neuropsychiatric disorders
NMDA receptor
PET
RADIATION-DOSIMETRY
LIGAND

Access to Document

10.1186/s13550-022-00925-8Licence: CC BY 4.0

https://phaidra.univie.ac.at/o:1673247Licence: CC BY 4.0

Cite this

Rischka, L., Murgaš, M., Pichler, V., Vraka, C., Rausch, I., Winkler, D., Nics, L., Rasul, S., Silberbauer, L. R., Reed, M. B., Godbersen, G. M., Unterholzner, J., Handschuh, P., Gryglewski, G., Mindt, T., Mitterhauser, M., Hahn, A., Ametamey, S. M., Wadsak, W., ... Hacker, M. (2022). Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[¹¹C]Me-NB1. EJNMMI Research, 12(1), Article 53. https://doi.org/10.1186/s13550-022-00925-8

@article{8178965e3f484fdabbd478c808328140,

title = "Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1",

keywords = "Biodistribution, Dosimetry, GluN2B-subunit, Neuropsychiatric disorders, NMDA receptor, PET, RADIATION-DOSIMETRY, LIGAND",

author = "Lucas Rischka and Matej Murga{\v s} and Verena Pichler and Chrysoula Vraka and Ivo Rausch and Dietmar Winkler and Lukas Nics and Sazan Rasul and Silberbauer, \{Leo Robert\} and Reed, \{Murray Bruce\} and Godbersen, \{Godber Mathis\} and Jakob Unterholzner and Patricia Handschuh and Gregor Gryglewski and Thomas Mindt and Markus Mitterhauser and Andreas Hahn and Ametamey, \{Simon Mensah\} and Wolfgang Wadsak and Rupert Lanzenberger and Marcus Hacker",

note = "Funding Information: This project was supported in part by the Swiss National Science Foundation grant numbers 310030E-160403/1 and 310030E-182872/1 to Prof. Simon M. Ametamey. Matej Murga{\v s} is funded by the Austrian Science Fund FWF DOC 33-B27. Murray B. Reed and Leo R. Silberbauer are recipients of a DOC fellowship of the Austrian Academy of Sciences. Funding Information: The authors are particularly grateful to Pia Baldinger-Melich and Paul Michenthaler for clinical support. We thank Vera Ritter, Christoph Wotawa, Daniel Pacher, Sebastian Klug, Harald Ibeschitz, Natalie Schindler, Karsten Bamminger, Tim Wollenweber and Marius Ozenil for technical support. Furthermore, the authors also thank Yves Auberson and Nicholas Seneca from Novartis for their technical support. Funding Information: S. M. Ametamey is co-inventor of the filed patent number US2017/0224852A1. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue. Without relevance to this work, W. Wadsak received within the last 3 years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (F{\"u}rstenfeldbruck, Germany). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

doi = "10.1186/s13550-022-00925-8",

language = "English",

volume = "12",

journal = "EJNMMI Research",

issn = "2191-219X",

publisher = "SPRINGEROPEN",

number = "1",

}

Rischka, L, Murgaš, M, Pichler, V, Vraka, C, Rausch, I, Winkler, D, Nics, L, Rasul, S, Silberbauer, LR, Reed, MB, Godbersen, GM, Unterholzner, J, Handschuh, P, Gryglewski, G, Mindt, T, Mitterhauser, M, Hahn, A, Ametamey, SM, Wadsak, W, Lanzenberger, R & Hacker, M 2022, 'Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[¹¹C]Me-NB1', EJNMMI Research, vol. 12, no. 1, 53. https://doi.org/10.1186/s13550-022-00925-8

TY - JOUR

T1 - Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1

AU - Rischka, Lucas

AU - Murgaš, Matej

AU - Pichler, Verena

AU - Vraka, Chrysoula

AU - Rausch, Ivo

AU - Winkler, Dietmar

AU - Nics, Lukas

AU - Rasul, Sazan

AU - Silberbauer, Leo Robert

AU - Reed, Murray Bruce

AU - Godbersen, Godber Mathis

AU - Unterholzner, Jakob

AU - Handschuh, Patricia

AU - Gryglewski, Gregor

AU - Mindt, Thomas

AU - Mitterhauser, Markus

AU - Hahn, Andreas

AU - Ametamey, Simon Mensah

AU - Wadsak, Wolfgang

AU - Lanzenberger, Rupert

AU - Hacker, Marcus

N1 - Funding Information: This project was supported in part by the Swiss National Science Foundation grant numbers 310030E-160403/1 and 310030E-182872/1 to Prof. Simon M. Ametamey. Matej Murgaš is funded by the Austrian Science Fund FWF DOC 33-B27. Murray B. Reed and Leo R. Silberbauer are recipients of a DOC fellowship of the Austrian Academy of Sciences. Funding Information: The authors are particularly grateful to Pia Baldinger-Melich and Paul Michenthaler for clinical support. We thank Vera Ritter, Christoph Wotawa, Daniel Pacher, Sebastian Klug, Harald Ibeschitz, Natalie Schindler, Karsten Bamminger, Tim Wollenweber and Marius Ozenil for technical support. Furthermore, the authors also thank Yves Auberson and Nicholas Seneca from Novartis for their technical support. Funding Information: S. M. Ametamey is co-inventor of the filed patent number US2017/0224852A1. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue. Without relevance to this work, W. Wadsak received within the last 3 years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (Fürstenfeldbruck, Germany). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

KW - Biodistribution

KW - Dosimetry

KW - GluN2B-subunit

KW - Neuropsychiatric disorders

KW - NMDA receptor

KW - PET

KW - RADIATION-DOSIMETRY

KW - LIGAND

UR - https://www.scopus.com/pages/publications/85137074615

U2 - 10.1186/s13550-022-00925-8

DO - 10.1186/s13550-022-00925-8

M3 - Article

AN - SCOPUS:85137074615

SN - 2191-219X

VL - 12

JO - EJNMMI Research

JF - EJNMMI Research

IS - 1

M1 - 53

ER -